Antibiotic Resistance Alert: The World Health Organization (WHO) is calling for urgent innovation in antibacterial agents as antimicrobial resistance (AMR) threatens global health. Our EVQ-218 nanoparticle is intended to address this critical need, demonstrating efficacy against the WHO's top six antibiotic-resistant strains, without triggering AMR. In vitro studies found EVQ-218 demonstrated efficacy against a range of pathogens, including the top six antibiotic-resistant strains identified by WHO.* EVQ-218 offers hope in combating drug-resistant infections. 🔗 Learn More: https://lnkd.in/g-ctBabb *Data on file. #Nanotechnology #SuperBugs #AMR #AntibioticResistantBacteria #GlobalFight
About us
EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries. The company’s multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. EVŌQ Nano is currently focused on developing nanoparticles for 3 core industries: EVŌQ Bio has developed an inhaled therapeutic using EVQ-218 for the treatment of pulmonary bacterial infections in patients with cystic fibrosis. The company recently completed a successful Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration and is confidently advancing toward Phase I clinical trials. EVŌQ MedTech integrates antimicrobial capabilities into medical devices to defend against a broad spectrum of contaminants like bacteria and fungi. The team is collaborating with leading catheter manufacturers with the aim of curbing healthcare-associated infections (HAIs), impacting more than 1 million hospital patients annually. FUZE Technologies serves the textile, hospitality, fitness, and workspace industries. Its EPA-approved antimicrobial technology is free of chemicals, toxicity, and environmental waste. FUZE is working with some of the world’s most notable brands, including Nike, Adidas, the New England Patriots, Marriott, and Hilton.
- Website
-
http://evoqnano.com
External link for EVŌQ Nano
- Industry
- Nanotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Salt Lake City, Utah
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
Get directions
1895 W 2100 S
Suite 100
Salt Lake City, Utah 84119, US
Employees at EVŌQ Nano
Updates
-
2024 marked a pivotal year for EVŌQ Nano as we advanced our antimicrobial nanoparticle platform. As we welcome 2025, we remain laser-focused on combating antimicrobial resistance (AMR) and its global health impact. Thank you to our dedicated team, partners, and supporters who share our vision. #HappyNewYear #AMR #Nanoparticle #Antimicrobial #GlobalHealth
-
-
Compared to traditional nanosilvers, EVQ-218 is differentiated as the first stable, nonemissive, pure silver nanoparticle that meets the highest standards set by the National Institute of Standards and Technology (NIST), making it a superior candidate for biomedical and consumer product use. View our full EVQ-218 infographic here:https://lnkd.in/gymQbghC #AMR #Antimicrobial #Nanoparticle #Innovation #Biomedical
-
-
Current antibacterial catheters externally coated with silver lose efficacy once inserted, due to natural sloughing of the material coupled with the short life of silver ion emissions. This combination hinders the antimicrobial activity of current products. By embedding our nanoparticles directly into the polymer used to make tubing and catheters, manufacturers can combat drug-resistant bacteria and significantly reduce healthcare-associated infections. #Antimicrobial #AMR #MedicalDevices #Innovation #Nanoparticles #DrugResistant #HAIs
-
-
For the medical device industry, antimicrobial protection can be incorporated across the manufacturing pipeline to combat healthcare-associated infections (HAIs), affecting over 1 million patients annually. Our novel nanoparticle EVQ-218 demonstrates antimicrobial efficacy in four unique application methods: 1. Integrated during the synthesis process of raw materials 2. Incorporated into polymer pellets for material production 3. Applied to finished medical devices postproduction 4. Added to surface modification coatings to enhance performance #MedicalDevice #Antimicrobial #Nanoparticle #Innovation #HAIs #AMR
-
-
Did you know? Our proprietary nanoparticle, EVQ-218, was characterized as a new form of silver by the American Chemical Society journal, ACS Omega. EVQ-218 is the first and only non-ionic silver nanoparticle with effective antimicrobial action devoid of cytotoxicity. The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. #SuperBugs #AMR #AntimicrobialResistance #Innovation #Silver #Nanoparticle
-
-
At EVŌQ Nano, we engineer novel nanoparticles for the life, materials, and textile science industries. Our antimicrobial nanotech platform is demonstrating success in a wide range of applications, from medical devices to therapeutics to textiles. Learn more about our core initiatives at evoqnano.com #Innovation #Nanoparticles #Antimicrobial #MedicalDevices #Therapeutics #Textiles
-
-
At EVŌQ Nano, we’re committed to addressing the growing threat of antimicrobial resistance (AMR) through innovative solutions like our EVQ-218 nanoparticle, designed to combat multidrug-resistant bacteria without triggering AMR. Tackling AMR requires global collaboration and novel approaches. We applaud TAXIS Pharmaceuticals, Inc. for their work in developing new classes of anti-resistance agents to treat life-threatening bacterial infections. #AMR #AntimicrobialResistance #DrugResistance #Innovation #Nanoparticle
Antimicrobial Resistance in War Zones: A Growing Global Health Threat War-torn regions like Ukraine are becoming breeding grounds for drug-resistant bacteria, amplifying the global challenge of antimicrobial resistance (AMR).🌍 The conditions in these areas—overburdened healthcare systems, widespread antibiotic misuse, and limited infection control—create the perfect storm for the rise of lethal, drug-resistant pathogens. Tackling AMR in such environments requires global collaboration, innovative treatments, and a commitment to public health solutions. 🤝 TAXIS Pharmaceuticals, Inc. is a clinical-stage biotech company developing new classes of anti-resistance agents to treat life-threatening, multidrug-resistant bacterial infections. Whether from overuse or underuse, it's going to take a global effort to beat AMR! Read how TAXIS is racing to save lives here https://bit.ly/3BwkzQ4. 🦠 Read more about the crisis zones are quickly furthering AMR in Science Magazine's article by Richard Stone here: War-torn Ukraine Has Become a Breeding Ground for Lethal Drug-Resistant Bacteria https://bit.ly/4gqAeiS #AMR #AntimicrobialResistance #DrugResistance #antibioticresistance #antibiotics #healthcare #HealthcareInnovation #war #medicine #globalhealth #worldhealth #infection World Health Organization Centers for Disease Control and Prevention
-
-
Ever wonder why some bacterial infections are so hard to treat? The answer often lies in biofilms —protective layers that bacteria build to shield themselves from antibiotics and the body’s immune system. Our breakthrough nanoparticle, EVQ-218, demonstrates efficacy against biofilm formation, making it a promising candidate for tackling difficult-to-treat infections. Learn more: https://lnkd.in/dkW7vMCb #AMR #Biofilms #Innovation #AntimicrobialResistance #Antibiotics #SuperBugs
-
Our CEO, Shaun Rothwell, recently had a great conversation with Steve Maxson on the MedTech Unboxed podcast to share how our cutting-edge nanoparticle technology can protect against device-related infections. #MedTechUnboxed #AntimicrobialResistance #AMR #Innovation #HAIs
This week, we’re releasing episode #7 of MedTech Unboxed, with Shaun Rothwell, CEO of EVŌQ Nano. In this episode, Shaun discusses how their EVQ-218 silver nanoparticle antimicrobial platform has the potential to significantly combat healthcare-associated infections (HAIs) and reduce thrombosis. HAIs impact over 1 million hospital patients annually, resulting in significant morbidity, mortality, and approximately $10 billion in healthcare costs each year. According to Shaun, over 20,000 people die every year from urinary catheter infections in the US alone. Our discussion includes: ➡️ Overview of the EVQ-218 silver nanoparticle technology (non-ionic) and why it is superior to conventional silver ions in inhibiting bacterial growth. ➡️ Efforts to reduce HAIs in indwelling catheters by preventing bacteria colonization and biofilm formation on catheter surfaces. ➡️ How EVQ-218 nanoparticles enhance antithrombotic properties in coatings to minimize the risk of blood coagulation. ➡️ Using high energy lasers to manufacture spherical nanoparticles at scale with high consistency in their new 60,000 square foot facility in Salt Lake City. Listen to the full episode here: https://lnkd.in/ehS5_aiQ #MedTechUnboxed #antimicrobialresistance #antimicrobial #AMR #HAIs